In contrast to the current purely pharmacological dogma for CKD, such as relying on angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and SGLT2 inhibitors, which often leads to almost inevitable progression towards renal failure, KMT may have the potential of CKD remission, which should be investigated in more and larger clinical trials. Here, SLC5A2 is linked to Renal insufficiency.